Bruker (NASDAQ:BRKR) Posts Quarterly Earnings Results

Bruker (NASDAQ:BRKR) issued its earnings results on Thursday. The medical research company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06), FiscalAI reports. The business had revenue of $977.20 million during the quarter, compared to analysts’ expectations of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.Bruker’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.76 EPS. Bruker updated its FY 2026 guidance to 2.100-2.150 EPS.

Here are the key takeaways from Bruker’s conference call:

• FY2026 guidance — Bruker expects reported revenue of $3.57–$3.60B (4%–5% growth), 1%–2% organic growth, a 250–300 bps non‑GAAP operating margin improvement, and 15%–17% non‑GAAP EPS growth (23%–25% CER), while acknowledging an ~8% currency EPS headwind.
• Strong Q4 cash and deleveraging — Q4 operating cash flow was ~ $230M with free cash flow of $207M, the company repaid ~$145M of debt and finished 2025 with ~ $300M in cash and a leverage ratio of ~3.1.
• Order momentum and strategic wins — BSI book‑to‑bill was >1.0 for two consecutive quarters with ~7 months of BSI backlog, strong semi‑metrology orders, double‑digit spatial biology orders, and >$500M in multi‑year BEST superconducting‑wire agreements booked.
• Lingering headwinds and near‑term weakness — 2025 organic revenue declined (full year down 3.7%, Q4 organic down 5.1%), margins were pressured by tariffs, unfavorable mix and currency (gross margin down ~310 bps in Q4), and management expects Q1 2026 organic revenue to decline mid‑single digits before recovery later in the year.

Bruker Stock Down 2.7%

Shares of BRKR stock opened at $36.51 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.91. The company’s fifty day moving average price is $46.92 and its 200-day moving average price is $40.50. The company has a market capitalization of $5.55 billion, a price-to-earnings ratio of -243.40, a PEG ratio of 4.87 and a beta of 1.19. Bruker has a one year low of $28.53 and a one year high of $56.22.

Trending Headlines about Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Q4 revenue beat and conservative upside in full‑year revenue guidance — Bruker reported Q4 revenue of $977.2M, above consensus, and issued FY2026 revenue guidance of about $3.6B (above street revenue consensus), which supports top‑line growth expectations. Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Strategic partnership in India to expand spatial biology presence — Bruker partnered with Premas Life Sciences to strengthen tissue research capabilities in India, which could support regional growth and recurring consumable/service revenue. Premas Life Sciences Partners with Bruker Spatial Biology
• Neutral Sentiment: Company released earnings presentation and slide deck — management’s slides and call are available for detail on segments and margin outlook; useful for judging whether revenue guidance is sustainable. Earnings Call Presentation
• Neutral Sentiment: Short‑interest data reported but appears anomalous — filings in mid‑February show zero shares/NaN changes (likely data/reporting noise), so don’t read meaningfully into a short squeeze risk from these entries.
• Negative Sentiment: EPS missed expectations and earnings declined year‑over‑year — Q4 EPS was $0.59 vs. consensus ~$0.65 and vs. $0.76 a year ago, highlighting near‑term margin pressure. Q4 Earnings Miss
• Negative Sentiment: Analysts trimmed forecasts and price targets after the print — multiple analysts lowered estimates and TD Cowen cut its price target from $53 to $43 and moved to a “hold,” which likely pressured the stock. These Analysts Cut Their Forecasts On Bruker TD Cowen note (summary)

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 7,000 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $55.00, for a total value of $385,000.00. Following the completion of the transaction, the vice president directly owned 128,443 shares in the company, valued at $7,064,365. This represents a 5.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 27.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

Large investors have recently added to or reduced their stakes in the stock. Parkside Financial Bank & Trust increased its position in Bruker by 144.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,482 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 876 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Bruker in the 4th quarter worth approximately $51,530,000. Inspire Advisors LLC bought a new stake in Bruker during the 4th quarter valued at $305,000. UMB Bank n.a. grew its stake in Bruker by 57.9% in the fourth quarter. UMB Bank n.a. now owns 1,571 shares of the medical research company’s stock valued at $74,000 after purchasing an additional 576 shares during the last quarter. Finally, First Trust Advisors LP raised its stake in shares of Bruker by 42.9% during the 4th quarter. First Trust Advisors LP now owns 1,126,866 shares of the medical research company’s stock worth $53,087,000 after acquiring an additional 338,217 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on BRKR shares. Zacks Research upgraded shares of Bruker from a “strong sell” rating to a “hold” rating in a report on Monday, December 8th. TD Cowen dropped their price target on Bruker from $53.00 to $43.00 and set a “hold” rating on the stock in a research report on Friday. Wolfe Research raised shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 target price for the company in a research note on Wednesday, December 10th. Bank of America lifted their price target on Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Finally, Rothschild & Co Redburn set a $60.00 target price on Bruker in a research note on Thursday, November 20th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Bruker has a consensus rating of “Hold” and a consensus target price of $50.38.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.